Bladder Cancer

Bladder cancer is the sixth most common cancer in the U.S.

The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The Food and Drug Administration has granted accelerated approval for durvalumab for treatment of patients with bladder cancer.

The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.

In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.

In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.

Charles Drake, M.D., Ph.D.. is optimistic about immunotherapy as it continues to move toward the frontline setting in GU cancers.

The FDA granted avelumab a priority review to a biologics license application to treat some patients with metastatic urothelial carcinoma, according to the developers of the drug.

Cabometyx combinations showed activity in patients with GU cancers, according to a preliminary clinical study.

Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.

Checkpoint inhibitors drastically changed the treatment landscape of urothelial carcinoma, and more changes are on the way.

The FDA granted Keytruda a priority review for the treatment of some patients with urothelial carcinoma.

Opdivo was granted an accelerated approval for a subset of patients with urothelial carcinoma.

After results from a phase 3 trial showed that Keytruda improved overall survival, it may become the next standard of care for patients with advanced urothelial carcinoma.

The FDA recently issued a warning that a type of medicine used to treat Type 2 diabetes may increase a person's risk for developing bladder cancer.

Tecentriq (atezolizumab) is being reviewed for the use in additional settings to treat bladder cancer.

The PD-L1 inhibitor durvalumab was granted a priority review for the treatment of some patients with urothelial carcinoma.

As immunotherapy's potential continues to grow in the treatment of bladder cancer, Gopa Iyer, M.D., says that more research needs to be done before it becomes the next new standard.

The treatment landscape of bladder cancer drastically changed this spring with the approval of an immunotherapy agent, and will continue to shift in the months and years to come.

One company's production of a popular bladder cancer therapy is set to halt by mid-2017, generating worries from patients and oncologists that there will be a shortage.

The combination of Opdivo and Yervoy is showing promise in the treatment of bladder cancer, according to a recent study.

The National LGBT Cancer Network is making cancer screenings more available to a high-risk, underserved population.

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

When it comes to bladder cancer, PD-1 and PD-L1 agents will become the new mainstay, says Jonathan E. Rosenberg, M.D.